{"product_id":"global-biologics-contract-development-market-size-study-forecast-by-source-microbial-mammalian-others-by-product-service-cell-line-development-process-development-others-by-disease-indication-oncology-immunological-disorders-cardiovascular","title":"Global Biologics Contract Development Market Size Study \u0026 Forecast, By Source (Microbial, Mammalian, Others), by Product Service (Cell Line Development, Process Development, Others), by Disease Indication (Oncology, Immunological Disorders, Cardiovascular","description":"\u003cp\u003eGlobal Biologics Contract Development Market Size Study \u0026amp; Forecast, By Source (Microbial, Mammalian, Others), by Product Service (Cell Line Development, Process Development, Others), by Disease Indication (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others) and Regional Analysis, 2023-2030\u003cbr\u003e\nGlobal Biologics Contract Development Market is valued at approximately USD 6.08 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.5% over the forecast period 2023-2030. Biologics contract development refers to the outsourcing of development and manufacturing services for biologic drugs or therapies to contract development and manufacturing organizations (CDMOs) or contract research organizations (CROs). Biologics are complex molecules derived from living organisms, including proteins, antibodies, vaccines, and gene therapies. The rising adoption of advanced technology for biological production is acting as a catalyzing factor for market growth. Furthermore, increased drug development methods by pharmaceutical companies, increased drug approval rates by the Food and Drug Administration, increased use of targeted pharmacological therapies, and increased desire for personalized medication are some of the factors resulting in the increase in market growth.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, the surging prevalence of diseases such as neurological illnesses, gynecological disorders, cancer, ophthalmic disorders, and cardiovascular disorders are contributing to the market development across the globe. According to World Health Organization in 2022, cancer is one of the main causes of death worldwide, accounting for over 10 million deaths in 2020. According to Cancer Tomorrow predictions in 2020, approximately 19.3 million cancer cases were reported in 2020, with this figure anticipated to climb to 30.2 million by 2040. In such circumstances, healthcare CDMOs play an important role in patient care because many biopharma companies aspire to develop novel medicines or first-in-class products for illness treatment. Furthermore, an increase in the adoption of advanced technologies for biologic development, a favorable environment for clinical trials in developing countries, an increase in the number of collaborations, contracts, and mergers with local players to develop advanced biologic products, and an increase in the development of greater manufacturing flexibility in the biopharmaceutical sector is expected to provide lucrative opportunities for market growth over the forecasting period. However, the high cost of biologics production processes, as well as a lack of understanding about the usage of these products, limit the growth of the biologics contract development industry.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Biologics Contract Development Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East \u0026amp; Africa. North America is expected to lead the market in 2021. Strategic collaborations and acquisitions, as well as growing demand for specialized testing services, are driving the market. The growth of contract development organizations (CDOs) can be attributed mostly to the region's increased clinical trial and outsourcing activity. Furthermore, the high prevalence of chronic diseases is substantial fostering the demand for clinical studies in this region. These factors drive market expansion. Asia Pacific is expected to be the fastest growing region during the forecast period, because of different regulatory organization adjustments to update clinical trial evaluation standards based on global needs, biotechnology businesses are investing in the Asia Pacific region.\u003c\/p\u003e\n\n\u003cp\u003eMajor market players included in this report are:\u003cbr\u003e\nWuXi Biologics\u003cbr\u003e\nAbzena Ltd\u003cbr\u003e\nFujifilm Diosynth Biotechnologies\u003cbr\u003e\nKBI Biopharma, Inc.\u003cbr\u003e\nAGC Biologics\u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nCuria Global, Inc.\u003cbr\u003e\nGenscript\u003cbr\u003e\nBionova Scientific, Inc.\u003cbr\u003e\nBioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\nIn September 2020, Almac Group recently announced the beginning of a contract for testing and development services for biologics. The development and testing of new biologic products will benefit from this expansion.\u003c\/p\u003e\n\n\u003cp\u003eIn February 2020,  Lake Pharma In., Inc. has announced the debut of combined chemistry and biologics services, for faster antibody-drug conjugates development solutions for the pharmaceutical and biotechnology sectors.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Biologics Contract Development Market Report Scope:\u003cbr\u003e\nHistorical Data – 2020 - 2021\u003cbr\u003e\nBase Year for Estimation – 2022\u003cbr\u003e\nForecast period - 2023-2030\u003cbr\u003e\nReport Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered – Source, Product Services, Disease Indication, Region\u003cbr\u003e\nRegional Scope - North America; Europe; Asia Pacific; Latin America; Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e \n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.\u003c\/p\u003e \n\n\u003cp\u003eThe detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Source:\u003cbr\u003e\nMicrobial\u003cbr\u003e\nMammalian\u003cbr\u003e\nOthers\u003cbr\u003e\nBy Product Service:\u003cbr\u003e\nCell Line Development\u003cbr\u003e\nProcess Development\u003cbr\u003e\nOthers\u003cbr\u003e\nBy Disease Indication:\u003cbr\u003e\nOncology\u003cbr\u003e\nImmunological Disorders\u003cbr\u003e\nCardiovascular Disorders\u003cbr\u003e\nHematological Disorders\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia \u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003cbr\u003e\nSaudi Arabia\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nRest of Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nWuXi Biologics\u003c\/p\u003e\n\n\u003cp\u003eAbzena Ltd\u003c\/p\u003e\n\n\u003cp\u003eFujifilm Diosynth Biotechnologies\u003c\/p\u003e\n\n\u003cp\u003eKBI Biopharma, Inc.\u003c\/p\u003e\n\n\u003cp\u003eAGC Biologics\u003c\/p\u003e\n\n\u003cp\u003eThermo Fisher Scientific Inc.\u003c\/p\u003e\n\n\u003cp\u003eCuria Global, Inc.\u003c\/p\u003e\n\n\u003cp\u003eGenscript\u003c\/p\u003e\n\n\u003cp\u003eBionova Scientific, Inc.\u003c\/p\u003e\n\n\u003cp\u003eBioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"July, 2023 \/ 200 Pages \/ MCW16231484","offer_id":47647319490866,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true},{"title":"July, 2023 \/ 200 Pages \/ MCW16231485","offer_id":47647319523634,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-biologics-contract-development-market-size-study-forecast-by-source-microbial-mammalian-others-by-product-service-cell-line-development-process-development-others-by-disease-indication-oncology-immunological-disorders-cardiovascular","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}